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Thirteen years ago the first decoy receptor
was identified (ie, IL-1 receptor type II).
Lacking a cytoplasmic domain, it binds IL-
1b, without triggering signal transduction.
Thus the receptor was defined as “struc-
turally incapable of transducing signal but
able to recognise the agonist with high
affinity and specificity”1 acting as a “sink”
to prevent ligand activity. Since then,
other cytokines and chemokines (mostly
pro-inflammatory) have been found to be
similarly regulated.2 Their mechanism of
action is to compete with functional
receptors for ligand binding and in some
instances target the complex for
degradation. Several decoy receptors for
the chemokine family have been identified
(eg, D6, DARC and CCXCKR). Common
to all are mutations in or around the DRY
motif that prevent G protein coupling and
intracellular signal transduction.
D6 was first cloned in 19973 and
its designation is that of the clone from
which the cDNAwas isolated (G Graham,
personal communication, 13 August 2009).
In D6 the DRYLAIV motif is replaced to
DKYLEIV and just one substitution to
DKYLAIV restores weak signal trans-
duction capacity.4 D6 scavenges pro-
inflammatory CC chemokines (ie,
CCL2,3,4,7,8,11,13,17,22,23,24, CCL3L1)
while sparing homeostatic CC chemo-
kines, or those from other subfamilies.1 To
accomplish this, D6 constitutively shut-
tles to and from the cell surface via
recycling endosomes. Sensitive to the low
pH of endosomes, internalised chemokines
are released and degraded, allowing D6 to
return to the cell surface, in a process
analogous to a “tapis roulant”.1
D6 is expressed by lymphatic endothelial
cells (LEC) at sites of primary antigen
exposure, such as the gut, skin, lung and
placenta. In health, D6 is mostly found in
intracellular vesicles, from where it rapidly
cycles to the cell membrane upon exposure
to inflammatory CC chemokines.4 D6
expression has been thought to be
restricted to afferent LEC. But its function
as a chemokine scavenger at this sole loca-
tion is not obvious, as chemokines appear
sufficiently separated by intervening tissue
to be scavenged by LECD65 (hypothesis A)
(figure 1). Recently, expression of D6 has
been demonstrated on leukocytes,
predominantly on B cells and dendritic cells
within inflamed tissues. By contrast, these
will be critically positioned to act as
chemokine scavengers (hypothesis B). This
concept is now being challenged by the
work of Vetrano et al6 (see page 197).
RELATIVE ROLE OF LEUKOCYTE AND
LYMPHATIC D6
Vetrano observed that D6 expression is
increased in leukocytes and colonic
lymphatic vascular beds from inflamma-
tory bowel disease (IBD) and IBD-associ-
ated cancer.6 D6 also plays a role in dextran
sulfate sodium (DSS) colitis, as there is
greater inflammation and accumulation of
CC chemokines during DSS colitis in
D6-deficient mice, associated with
increased leukocytic infiltration and
weight loss. This is in keeping with prior
studies in which D6-deficient mice have
been shown to be more susceptible to
inflammatory-mediated tissue damage.7 8
Most importantly, they show that selec-
tive D6 deficiency on haematopoietic cells
had no impact on DSS colitis, while
restoration of D6 to the haematopoietic
compartment failed to rescue the exacer-
bation of colitis caused by D6 deficiency.
These findings suggest that in the context
of acute intestinal inflammation, expres-
sion of LECD6 and not haematopoietic D6
is critical to modulate colitis.
Impaired resolution of inflammation
likely contributes to chronic injury and
progression to malignancy. In fact, there is
a robust link between chronic inflamma-
tion and cancer. Along the gastrointestinal
tract, there is increased risk of oesophageal
adenocarcinoma associated with chronic
acid reflux, gastric cancer with Helicobacter
pylori infection, cholangiocarcinoma with
primary sclerosing cholangitis, hepatoma
with viral hepatitis, lymphoma with
coeliac disease and colon cancer with IBD.
A role for leukocyte-derived chemokines in
tumour initiation and progression has been
postulated. The composition of leukocyte
infiltrates in solid tumours is directly
related to the localised production of
chemokines, matrix metalloproteinases
and angiogenic factors which contribute to
tumour progression. CeC chemokines
CCL2, CCL4 and CCL5 directly induce
MMP9 production from macrophages and
all directly correlate with tumour progres-
sion in human breast and squamous-cell
carcinomas.9 Whether chemokine scav-
enging by D6 may play a role in these
processes is unknown. The data by Vetrano
and colleagues supports an affirmative
answer. D6-deficient mice displayed
increased susceptibility to azoxymethane-
induced colitis-associated colon cancer,
a greater number of active lesions,
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acceleratedepithelial cell turnover andaltered
expression of junctional proteins. Further-
more, the exacerbated disease severity in D6-
deficient mice correlated with increased
colonic leukocyte infiltration, supporting
a link between leukocyte-derived chemo-
kines and inflammation-related cancer.
Two aspects of decoy receptor biology are
critical to understand their role in intestinal
inflammation. First, D6 does not direct
a local immune response within the intes-
tine, but instead provides a modulatory
function. The chemokine scavenging
activity of D6 is a delayed response,
secondary to the induction of a pro-
inflammatory chemokine gradient, to limit
an overzealous immune response. Second,
a challenge in modulating the immune
response is immunosuppression, leading to
opportunistic infections. However, D6
binds only pro-inflammatory chemokines,
having no affinity for homeostatic chemo-
kines. Furthermore, expression of D6 is also
dependent on the chemokine gradient,
being thus self-regulated. In this way, D6
deficiencydoesnot increase susceptibility to
infection, despite an inability to adequately
decrease chemokine concentrations.10 D6
offers a potential therapeutic strategy for
the promotion of homeostasis in IBD,
which would indirectly reduce the risk of
colon cancer. Designing a new generation
of drugs that target a dysregulated immune
response, such as D6, without disturbing
immune surveillance and regulatory func-
tions remains a holy grail of immune-drug
design.
FUTURE DIRECTIONS
The manuscript by Vetrano provides
insight for a role of D6 in intestinal
inflammation and opens new avenues for
further investigation. A question that
remains unanswered is whether colon
cancer (not associated with IBD) will
similarly show increased D6 expression. But
most importantly, as D6 is not predomi-
nantly expressed by innate immune cells
(which constitute the predominant infil-
trating subset in acute DSS colitis), but
rather by B cells and dendritic cells,
exploring whether haematopoietic D6
might be more critical for the modulation
of inflammation in models where there is
larger role for the adaptive immune
response (ie, IL10/, TNFDARE or
SAMP1/Yit mice) is highly relevant.
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Figure 1 Alternative/complementary hypotheses for the role of D6 in intestinal inflammation. In
hypothesis A, expression of D6 on lymphatic endothelial cells (LEC) is critical to prevent tissue injury
due to sustained high levels of pro-inflammatory chemokines. The study by Vetrano et al6 supports
this hypothesis in an acute model of colonic inflammation. In the second hypothesis, co-expression
of D6 and CC chemokines on chronic inflammatory cells such as dendritic cells and B cells facilitates
their localisation to the site of greatest chemokine release that results in local removal of the
chemotactic stimulus. This hypothesis, though not critical in the DSS model, may reflect a role for D6
in conditions where the inflammatory infiltrate is more substantially composed of B cells and
dendritic cells. In either hypothesis failure of D6 to curb pro-inflammatory chemotaxis results in
exacerbation of tissue injury.
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